CELL & GENE THERAPY INSIGHTS

Preclinical/translational tools and strategies

Guest Editor:
Bruce Bunnell, Professor and Chair at UNT Health Science Center
Bruce Bunnell
Professor and Chair at UNT Health Science Center
<p>Bruce A Bunnell is a professor and Chair of the Department of Microbiology, Immunology and Genetics at the University of North Texas Health Science Center in Fort Worth, TX. Previously, he served as Director of the Tulane Center for Stem Cell Research and Regenerative Medicine and Professor in the Department of Pharmacology in the Tulane University School of Medicine. Dr. Bunnell obtained his PhD in Microbiology from the University of Alabama at Birmingham School of Medicine. He then pursued Postdoctoral Fellowship research at the Howard Hughes Medical Institute in the School of Medicine at the University of Michigan and the National Human Genome Research Institute at the National Institutes of Health in Bethesda, MD. Dr. Bunnell was an Assistant Professor at the Nationwide Children&rsquo;s Hospital Research Institute, part of the Ohio State University School of Medicine prior to joining the faculty at Tulane University in 2002. Dr. Bunnell&rsquo;s research program is focused on both the basic science and translational applications of adult stem cells isolated from the bone marrow and adipose tissue. Dr. Bunnell investigates use of mesenchymal stem cells (MSCs) isolated from the bone marrow or adipose tissue as a therapeutic intervention for both multiple sclerosis (MS) wound repair, lung injury and bone repair. He is particularly interested the interactions of MSC with the immune system and how the cells elicit robust anti-inflammatory effects in vivo. He is currently working towards a human clinical trials for the treatment of osteoarthritis, traumatic brain injury and MS with these cells. He has served as a reviewer of stem cell, regenerative medicine and tissue engineering grants for the National Institutes of Health, Department of Defense and several state funded programs including Maryland, New York, Virginia and Pennsylvania. He has also served on grant review panels for several foreign countries including Denmark, Ireland, Poland, Germany and Spain. Dr. Bunnell serves as an Editorial Board Member for several journals, including Stem Cells, BMC Genomics, and Regenerative Medicine.</p>
February 2021

  • Preclinical/translational tools & strategies

    Preclinical/translational tools & strategies

    24 February 2021
    Foreword
    Bruce A Bunnell
    Bruce A Bunnell
    Professor and Chair, Department of Microbiology, Immunology and Genetics, University if North Texas Health Science Center, Fort Worth, TX, USA 76107
    Bruce A Bunnell is a professor and Chair of the Department of Microbiology, Immunology and Genetics at the University of North Texas Health Science Center in Fort Worth, TX. Previously, he served as Director of the Tulane Center for Stem Cell Research and Regenerative Medicine and Professor in the Department of Pharmacology in the Tulane University School of Medicine. Dr. Bunnell obtained his PhD in Microbiology from the University of Alabama at Birmingham School of Medicine. He then pursued Postdoctoral Fellowship research at the Howard Hughes Medical Institute in the School of Medicine at the University of Michigan and the National Human Genome Research Institute at the National Institutes of Health in Bethesda, MD. Dr. Bunnell was an Assistant Professor at the Nationwide Children’s Hospital Research Institute, part of the Ohio State University School of Medicine prior to joining the faculty at Tulane University in 2002. Dr. Bunnell’s research program is focused on both the basic science and translational applications of adult stem cells isolated from the bone marrow and adipose tissue. Dr. Bunnell investigates use of mesenchymal stem cells (MSCs) isolated from the bone marrow or adipose tissue as a therapeutic intervention for both multiple sclerosis (MS) wound repair, lung injury and bone repair. He is particularly interested the interactions of MSC with the immune system and how the cells elicit robust anti-inflammatory effects in vivo. He is currently working towards a human clinical trials for the treatment of osteoarthritis, traumatic brain injury and MS with these cells. He has served as a reviewer of stem cell, regenerative medicine and tissue engineering grants for the National Institutes of Health, Department of Defense and several state funded programs including Maryland, New York, Virginia and Pennsylvania. He has also served on grant review panels for several foreign countries including Denmark, Ireland, Poland, Germany and Spain. Dr. Bunnell serves as an Editorial Board Member for several journals, including Stem Cells, BMC Genomics, and Regenerative Medicine.
  • On a mission to bring single-cell sequencing to cell and gene therapy

    C Silver
    Charlie Silver
    CEO and co-founder of Mission Bio
    24 February 2021
    Interview
  • Accelerating preclinical development for AAV based gene therapies: bridging the gap between discovery and clinical development

    L Rodino-Klapac
    Louise Rodino-Klapac
    Chief Scientific Officer, Sarepta Therapeutics, Inc.
    Dr. Rodino-Klapac is a gene therapy pioneer who has dedicated her professional life to advancing medicines designed to treat genetically based diseases. With professional experience across industry and academia, she is renowned for her contributions to molecular genetics and gene therapy that have advanced the field. She is author to a vast body of published, peer-reviewed work, the recipient of multiple awards, a National Institutes of Health (NIH) Fellow appointee, and current Board member of the Association for Regenerative Medicine, as well as a member of the American Society for Gene and Cell Therapy, the American Academy of Neurology, and the American Association for the Advancement of Science. She is the former head of the Laboratory for Gene Therapy Research at Nationwide Children’s Hospital, established the Gene Therapy Center of Excellence within Sarepta and leads the Company’s Gene Editing Innovation Center, directing a team of researchers to discover and develop novel gene replacement and gene editing therapies. She co-founded and served as chief scientific officer of Myonexus Therapeutics, a gene therapy company focused on limb-girdle muscular dystrophies acquired by Sarepta in 2019. She currently serves as Sarepta’s Executive Vice President, Chief Scientific Officer. Her work has led to 11 investigational new drug applications and she is the co-inventor of SRP-9001, an investigational micro-dystrophin gene therapy, and the inventor of five investigational gene therapies for limb-girdle muscular dystrophy. She is the inventor of over 50 U.S. and over 70 international published patent applications. She earned her Ph.D. in molecular genetics from the Ohio State University and graduated summa cum laude from Kings College in Wilkes-Barre, Pennsylvania, with a Bachelor of Science degree in Biology.
    24 February 2021
    Editorial
  • On a mission to bring single-cell sequencing to cell and gene therapy

    C Silver
    Charlie Silver
    CEO and co-founder of Mission Bio
    24 February 2021
    Podcast
  • Preclinical/translational tools & strategies

    B Bunnell
    Bruce A Bunnell
    Professor and Chair, Department of Microbiology, Immunology and Genetics, University if North Texas Health Science Center, Fort Worth, TX, USA 76107
    Bruce A Bunnell is a professor and Chair of the Department of Microbiology, Immunology and Genetics at the University of North Texas Health Science Center in Fort Worth, TX. Previously, he served as Director of the Tulane Center for Stem Cell Research and Regenerative Medicine and Professor in the Department of Pharmacology in the Tulane University School of Medicine. Dr. Bunnell obtained his PhD in Microbiology from the University of Alabama at Birmingham School of Medicine. He then pursued Postdoctoral Fellowship research at the Howard Hughes Medical Institute in the School of Medicine at the University of Michigan and the National Human Genome Research Institute at the National Institutes of Health in Bethesda, MD. Dr. Bunnell was an Assistant Professor at the Nationwide Children’s Hospital Research Institute, part of the Ohio State University School of Medicine prior to joining the faculty at Tulane University in 2002. Dr. Bunnell’s research program is focused on both the basic science and translational applications of adult stem cells isolated from the bone marrow and adipose tissue. Dr. Bunnell investigates use of mesenchymal stem cells (MSCs) isolated from the bone marrow or adipose tissue as a therapeutic intervention for both multiple sclerosis (MS) wound repair, lung injury and bone repair. He is particularly interested the interactions of MSC with the immune system and how the cells elicit robust anti-inflammatory effects in vivo. He is currently working towards a human clinical trials for the treatment of osteoarthritis, traumatic brain injury and MS with these cells. He has served as a reviewer of stem cell, regenerative medicine and tissue engineering grants for the National Institutes of Health, Department of Defense and several state funded programs including Maryland, New York, Virginia and Pennsylvania. He has also served on grant review panels for several foreign countries including Denmark, Ireland, Poland, Germany and Spain. Dr. Bunnell serves as an Editorial Board Member for several journals, including Stem Cells, BMC Genomics, and Regenerative Medicine.
    24 February 2021
    Foreword
  • Expediting novel ex vivo HSC gene therapies to the clinic: a preclinical perspective

    G Leoni,
    Giulia Leoni
    Preclinical Scientist at Orchard Therapeutics
    A Lambert,
    Andy Lambert
    at Orchard Therapeutics
    C Hudson et al.
    Charlotte Hudson
    Preclinical Scientist at Orchard Therapeutics
    24 February 2021
    Commentary
  • Identify and select optimal T cell phenotypes

    J Lovrgen
    James Lovrgen
    Vice President, Cell Therapy Marketing Berkeley Lights
    22 February 2021
    FastFacts
  • Beginning gene therapy preclinical development with the end in mind: from preclinical to economic modelling

    O Negre
    Olivier Negre, PhD
    Co-founder and Partner, Biotherapy Partners
    16 February 2021
    Interview
  • Modelling late-onset diseases with induced pluripotent stem cells: a matter of time management

    C Cossins,
    Charlotte Cossins
    University of Oxford, Sir William Dunn School of Pathology, South Parks Road, Oxford, OX1 3RE, UK
    P Fairchild
    Paul J Fairchild
    Author for correspondence University of Oxford, Sir William Dunn School of Pathology, South Parks Road, Oxford, OX1 3RE, UK paul.fairchild@path.ox.ac.uk
    15 February 2021
    Expert Insight
  • The T cell therapy field faces preclinical and translational R&D challenges as it targets more complex diseases

    G Waanders,
    Gary Waanders
    VP - Head of Investor Relations, Medigene Immunotherapies GmbH
    S Raffegerst,
    Silke Raffegerst
    Director - Molecular Medicine (MM) Medigene Immunotherapies GmbH
    P Prinz-Schulz et al.
    Petra Prinz-Schulz
    Director - ImmunoProfiling (iPRO), Medigene Immunotherapies GmbH
    15 February 2021
    Expert Insight
  • Animal models of disease: preclinical to clinical gene therapy translatability

    E Matsumoto Plata,
    Erika Matsumoto Plata
    Emergency Medicine Department, Wexham Park Hospital, Slough, UK
    C Plata-Salaman
    Carlos R Plata-Salamán
    Author for correspondence Chief Scientific Officer and Chief Medical Officer of Esteve, Torre ESTEVE, Passeig de la Zona Franca 109, 08038 Barcelona, Spain cplata@esteve.com
    11 February 2021
    Expert Insight